Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Prediction, screening and characterisation of novel bioactive, tetra-peptide matrikines 3

ABSTRACT: Prediction, screening and characterisation of novel bioactive, tetra-peptide matrikines 3

PROVIDER: PRJEB60347 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR10949333_1.fastq.gz	Fastqsanger.gz
	ERR10949333_2.fastq.gz	Fastqsanger.gz
	ERR10949334_1.fastq.gz	Fastqsanger.gz
	ERR10949334_2.fastq.gz	Fastqsanger.gz
	ERR10949335_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 30

Similar Datasets

Prediction, screening and characterisation of novel bioactive, tetra-peptide matrikines 1

Project description:Prediction, screening and characterisation of novel bioactive, tetra-peptide matrikines 1

| PRJEB60376 | ENA

Prediction, screening and characterisation of novel bioactive, tetra-peptide matrikines 2

Project description:Prediction, screening and characterisation of novel bioactive, tetra-peptide matrikines 2

| PRJEB60379 | ENA

Prediction, screening and characterisation of novel bioactive, tetra-peptide matrikines 3

Project description:Small peptides with amino acid sequences similar to native skin proteins can beneficially affect clinical appearance (wrinkles) and architecture (collagen and elastic fibre deposition and epidermal thickness). However, the discovery of new cosmetic peptides has not been underpinned by any guiding hypothesis. As endogenous extracellular matrix (ECM)-derived peptides (matrikines) produced during tissue remodelling can influence cell activity, we hypothesised that protease cleavage site prediction can identify putative novel matrikines. This RNA-seq data is the in vivo test part of an in silico to in vivo discovery pipeline, which enables the prediction and characterisation of peptide matrikines with therapeutic potential. We use this pipeline to identify two novel ECM peptides (GPKG and LSVD) which, in combination, act in vitro to enhance the transcription of ECM organisation and cell proliferation genes and in vivo to promote epithelial and dermal remodelling. This pipeline approach can both identify new matrikines and provide insights into the mechanisms underpinning tissue repair.

2023-11-15 | E-MTAB-12704 | biostudies-arrayexpress

Prediction, screening and characterisation of novel bioactive, tetra-peptide matrikines 1

Project description:Small peptides with amino acid sequences similar to native skin proteins can beneficially affect clinical appearance (wrinkles) and architecture (collagen and elastic fibre deposition and epidermal thickness). However, the discovery of new cosmetic peptides has not been underpinned by any guiding hypothesis. As endogenous extracellular matrix (ECM)-derived peptides (matrikines) produced during tissue remodelling can influence cell activity, we hypothesised that protease cleavage site prediction can identify putative novel matrikines. This RNA-seq data is the in vitro testing part of an in silico to in vivo discovery pipeline, which enables the prediction and characterisation of peptide matrikines with therapeutic potential. We use this pipeline to identify two novel ECM peptides (GPKG and LSVD) which, in combination, act in vitro to enhance the transcription of ECM organisation and cell proliferation genes and in vivo to promote epithelial and dermal remodelling. This pipeline approach can both identify new matrikines and provide insights into the mechanisms underpinning tissue repair.

2023-12-15 | E-MTAB-12711 | biostudies-arrayexpress

Prediction, screening and characterisation of novel bioactive, tetra-peptide matrikines 2

Project description:Small peptides with amino acid sequences similar to native skin proteins can beneficially affect clinical appearance (wrinkles) and architecture (collagen and elastic fibre deposition and epidermal thickness). However, the discovery of new cosmetic peptides has not been underpinned by any guiding hypothesis. As endogenous extracellular matrix (ECM)-derived peptides (matrikines) produced during tissue remodelling can influence cell activity, we hypothesised that protease cleavage site prediction can identify putative novel matrikines. This RNA-seq data is the in vitro testing part of an in silico to in vivo discovery pipeline, which enables the prediction and characterisation of peptide matrikines with therapeutic potential. We use this pipeline to identify two novel ECM peptides (GPKG and LSVD) which, in combination, act in vitro to enhance the transcription of ECM organisation and cell proliferation genes and in vivo to promote epithelial and dermal remodelling. This pipeline approach can both identify new matrikines and provide insights into the mechanisms underpinning tissue repair.

2023-12-15 | E-MTAB-12710 | biostudies-arrayexpress

ChIP-chip from Drosophila egg chambers using antibody recognizing tetra-acetylated histone H4

Project description:Chromatin immunoprecipitation of tetra-acetylated histone H4 followed by hybridization to genome-wide tiling microarrays demonstrated that tetra-acetylated H4 is enriched at the two chorion Drosophila amplicons in follicle cells (DAFC) as well as other non-amplified loci Comparison of tetra-acetylated H4 ChIP sample compared to input DNA for two different Drosophila strains

2011-05-27 | E-GEOD-29520 | biostudies-arrayexpress

ChIP-chip from Drosophila egg chambers using antibody recognizing tetra-acetylated histone H4

2011-05-27 | GSE29520 | GEO

The ‘PepSAVI-MS’ pipeline for natural product bioactive peptide discovery

Project description:The recent increase in extensively drug resistant bacterial pathogens and the associated increase of morbidity and mortality demonstrate the immediate need for new antibiotic backbones with novel mechanisms of action. Here, we report the development of the PepSAVI-MS pipeline for bioactive peptide discovery. This highly versatile platform employs bioinformatics, statistics, and mass spectrometry to identify bioactive peptide targets from complex biological samples. We validate the use of this platform through the successful identification of known bioactive peptides from a botanical species, Viola odorata. Using this pipeline, we have widened the known antimicrobial spectrum for V. odorata cyclotides, including antibacterial activity of cycloviolacin O2 against E. faecium and A. baumannii. We further demonstrate the broad applicability of the platform through the identification of novel anticancer activities for cycloviolacins by their cytotoxicity against ovarian, breast and prostate cancer cell lines.

2017-01-02 | PXD004780 | Pride

Tetra-Amelia with lung aplasia phenotype

Project description:Tetra-Amelia with lung aplasia phenotype

| PRJNA438127 | ENA

Bioactive Peptide Profiling in Commercial Collagen Hydrolysates: Comparative Analysis Using Targeted LC-MS/MS Quantification

Project description:The investigation of collagen hydrolysates (CHs) is essential due to their widespread use in health, cosmetic, and therapeutic industries, attributing to the presence of bioactive dipeptides (DPs) and tripeptides (TPs). This study developed a novel targeted LC-MS/MS method with propyl-chloroformate (PCF) derivatization to measure three bioactive peptides—Hydroxyprolyl-glycine (Hyp-Gly), Glycyl-prolyl-hydroxyproline (Gly-Pro-Hyp), and Prolyl-hydroxyproline (Pro-Hyp)—in CHs, with strong correlation coefficients (0.992, 1.000, and 0.995, respectively) and low limits of detection (LODs) of 1.40, 0.14, and 1.16 µM, respectively. Untargeted Data Dependent Acquisition (DDA) analyses measured peptide size distribution, while amino acid analysis assessed nutritional content. Analysis of ten commercial CHs revealed similar amino acid profiles but varied peptide lengths, indicating diverse hydrolysis conditions. Products with higher proportions of smaller peptides showed elevated levels of the targeted bioactive peptides, suggesting that smaller peptide size may increase bioactivity. These findings can inform the optimization of CH supplements, providing consumers with detailed peptide content for more informed choices.

2024-06-09 | PXD051699 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data